Mode
Text Size
Log in / Sign up

Oncology

864 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Dried blood spot metabolomics shows promising breast cancer detection performance in 2,734 participants
Oncology Cohort
Dried blood spot metabolomics shows promising breast cancer detection performance in 2,734 participants Finger-Prick Test Spots Breast Cancer Early
This cohort study evaluated untargeted metabolomic profiling of dried blood spots for breast cancer detection among 2,734 participants (114 …
A new at-home style blood test can spot breast cancer with just a finger prick, offering hope for earlier detection without clinic visits.
Prognostic Nutritional Index and HALP Score Predict Lymph Node Metastasis in Breast Cancer
Oncology Cohort
Prognostic Nutritional Index and HALP Score Predict Lymph Node Metastasis in Breast Cancer Low nutrition score predicts lymph node spread in breast cancer cases
This cohort study of 799 breast cancer patients found that 51.6% had lymph node metastasis (LNM).
A simple nutrition score predicts if breast cancer has spread to lymph nodes, helping doctors plan better care.
QDB method shows higher consistency than IHC for HER2 assessment in invasive breast cancer
Oncology Cohort
QDB method shows higher consistency than IHC for HER2 assessment in invasive breast cancer New Test Finds Hidden Breast Cancer Targets
This observational cohort study compared a Quantitative Dot Blot (QDB) method to immunohistochemistry (IHC) for HER2 assessment in patients …
Some women told their breast cancer lacks a key target may actually benefit from powerful drugs — a new test can finally tell the difference…
CPX-351 first-line therapy shows 61% overall response in therapy-related AML or AML with myelodysplastic-related changes
Oncology Cohort
CPX-351 first-line therapy shows 61% overall response in therapy-related AML or AML with myelodysplastic-related changes New AML Drug Shows Strong Response But Some Patients Face Higher Risk
This retrospective monocentric cohort study evaluated 60 consecutive patients treated with CPX-351 as first-line therapy for therapy-related…
A new leukemia drug helps most patients respond well, but those with high white blood cell counts or complex gene changes may face higher ri…
NDRG4 methylation in blood leukocytes associated with gastric cancer risk and prognosis in a case-control study
Oncology Case-Control
NDRG4 methylation in blood leukocytes associated with gastric cancer risk and prognosis in a case-control study Blood test reveals hidden risk factor for stomach cancer survival
This case-control study evaluated methylation of the NDRG4 gene in peripheral blood leukocytes among 310 gastric cancer patients and 300 con…
A simple blood test can now predict stomach cancer risk and how well chemotherapy will work for patients.
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
Oncology
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma New drugs for myeloma need a safety net to work well
This qualitative interview review synthesizes perspectives from ten hematologists/oncologists regarding bispecific antibody (BsAb) use in…
New powerful drugs treat myeloma better, but patients need a safety net to handle side effects and stay on track for a long time.
Software validation report shows single biomarkers often outperform panels for breast cancer diagnosis
Oncology
Software validation report shows single biomarkers often outperform panels for breast cancer diagnosis New Tool Finds the Tipping Point in Cancer Tests
This software validation report evaluates the TholdStormDX v0.0.1 tool across four diagnostic domains.
A new tool could help doctors decide exactly when a test result means cancer is likely — cutting down on missed cases and false alarms.
Narrative review suggests time-related biases may attenuate apparent vaccine survival benefits in cancer patients
Oncology
Narrative review suggests time-related biases may attenuate apparent vaccine survival benefits in cancer patients New math shows vaccine benefits in cancer care might be overstated
This narrative review and target trial emulation examines 3-year overall survival in cancer patients receiving COVID-19 vaccines versus thos…
A new look at the data reveals that timing errors made the vaccine look more powerful than it actually is for cancer patients.
Recurrence patterns in high-grade glioma after standard chemoradiotherapy: a retrospective review
Oncology
Recurrence patterns in high-grade glioma after standard chemoradiotherapy: a retrospective review Why tumors grow back inside the radiation beam, not just at the edges
This retrospective single-center review of 41 patients with high-grade glioma found that central recurrence was the most common pattern (36.…
New data shows brain tumors often return in the middle of the radiation zone, suggesting biology, not just targeting errors, drives failure.
Review highlights lack of comprehensive evaluation for atorvastatin anticancer mechanisms and therapeutic potential
Oncology Sys. Review
Review highlights lack of comprehensive evaluation for atorvastatin anticancer mechanisms and therapeutic potential Review finds lack of research on atorvastatin's anticancer potential
This narrative review discusses the potential anticancer mechanisms and therapeutic potential of atorvastatin.
A review notes that a comprehensive evaluation of atorvastatin's anticancer mechanisms and potential is currently lacking.
Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
Oncology Phase II
Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference Prostate Cancer Vaccine Strategy Shows Tumor Responses, But One Arm Adds Risk
This early Phase 2 trial evaluated pembrolizumab combined with pTVG-HP or pTVG-AR DNA vaccines in 60 patients with metastatic castration-res…
A two-vaccine strategy did not improve survival over a single vaccine in advanced prostate cancer, yet both approaches shrank tumors in some…
Double 8F ultrafine chest tubes reduced pain and complications compared to standard tubes in lung tumor patients
Oncology Cohort
Double 8F ultrafine chest tubes reduced pain and complications compared to standard tubes in lung tumor patients Smaller tubes mean less pain for lung tumor patients after surgery
This retrospective multicenter cohort study evaluated 1,076 lung tumor patients who underwent U-VATS.
Lung surgery patients feel significantly less pain and face lower bleeding risks when doctors use ultrafine drainage tubes instead of regula…